Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Up 2.9 %

Evoke Pharma stock opened at $5.32 on Friday. The stock has a market cap of $45.74 million, a P/E ratio of -2.91 and a beta of 0.39. Evoke Pharma has a twelve month low of $3.54 and a twelve month high of $17.88. The company’s 50-day moving average price is $4.80 and its two-hundred day moving average price is $5.67.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The company had revenue of $2.55 million during the quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.